[ad_1]
- Blinded interim data from VISIONARY-MS continue to support the potential of CNM-Au8 to drive meaningful neurological functional improvements in MS patients
- Interim REPAIR-MS results provide further evidence of CNM-Au8’s homeostatic effect on brain bioenergetics in MS patients
SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage…
[ad_2]
